12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Company News  |  Other News

Resverlogix cancer, autoimmune news

Resverlogix completed the spinout of its subsidiary RVX Therapeutics Inc. into newco Zenith Epigenetics Corp. Resverlogix shareholders received one Zenith share for each Resverlogix share held prior to the spinout. Resverlogix said...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >